Sign inCreate account

Report workspace tools

NCT02969655COMPLETEDanonymous

A 52-week, Phase III, Double-blind, Active-controlled, Parallel-group, Multi-center Study to Evaluate Efficacy and Safety of Daprodustat Compared to Darbepoetin Alfa in Japanese Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Are Currently ESA Users

Sponsor

Source record

GlaxoSmithKline

Phase

Source record

Phase III

Modality

AI-normalized

small molecule

Target

AI-normalized

Anemia associated with Chronic Kidney Disease (CKD)

Indication / condition

AI-normalized

Anaemia

Intervention

Source record

Daprodustat small, Daprodustat small placebo, Daprodustat large, Daprodustat large placebo, Darbepoetin alfa, Darbepoetin alfa placebo

Source & freshness

Source record

NCT ID

NCT02969655

Original source

ClinicalTrials.gov

Source last updated

Nov 27, 2020

Ingested at

May 31, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT02969655

Title

A 52-week, Phase III, Double-blind, Active-controlled, Parallel-group, Multi-center Study to Evaluate Efficacy and Safety of Daprodustat Compared to Darbepoetin Alfa in Japanese Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Are Currently ESA Users

Sponsor

GlaxoSmithKline

Status

COMPLETED

Phase

Phase III

Condition raw

Anaemia

Condition normalized

Anaemia

Modality raw

Anaemia

Modality normalized

small molecule

Target raw

Anemia associated with Chronic Kidney Disease (CKD)

Target normalized

Anemia associated with Chronic Kidney Disease (CKD)

Interventions

Daprodustat small, Daprodustat small placebo, Daprodustat large, Daprodustat large placebo, Darbepoetin alfa, Darbepoetin alfa placebo

Public preview

Source record

The clinical trial evaluated the efficacy and safety of daprodustat compared to darbepoetin alfa in Japanese hemodialysis-dependent patients with anemia related to CKD. The study aimed to demonstrate non-inferiority of daprodustat to the standard treatment, darbepoetin alfa, over a 52-week period.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A 52-week, Phase III, Double-blind, Active-controlled, Parallel-group, Multi-center Study to Evaluate Efficacy and Safety of Daprodustat Compared to Darbepoetin Alfa in Japanese Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Are Currently ESA Users

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT02969655

Status

COMPLETED

Phase

Phase III

Sponsor

GlaxoSmithKline

Executive brief

Investment-Ready Snapshot

The clinical trial evaluated the efficacy and safety of daprodustat compared to darbepoetin alfa in Japanese hemodialysis-dependent patients with anemia related to CKD. The study aimed to demonstrate non-inferiority of daprodustat to the standard treatment, darbepoetin alfa, over a 52-week period.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedNov 27, 2020
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT02969655

Indication

Anaemia

Modality

small molecule

Target

Anemia associated with Chronic Kidney Disease (CKD)

Intervention

Daprodustat small, Daprodustat small placebo, Daprodustat large, Daprodustat large placebo, Darbepoetin alfa, Darbepoetin alfa placebo

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.